0001143313-22-000071.txt : 20221201
0001143313-22-000071.hdr.sgml : 20221201
20221201102622
ACCESSION NUMBER: 0001143313-22-000071
CONFORMED SUBMISSION TYPE: 25-NSE
PUBLIC DOCUMENT COUNT: 2
FILED AS OF DATE: 20221201
DATE AS OF CHANGE: 20221201
EFFECTIVENESS DATE: 20221201
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Renovacor, Inc.
CENTRAL INDEX KEY: 0001799850
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 25-NSE
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39271
FILM NUMBER: 221437743
BUSINESS ADDRESS:
STREET 1: 201 BROADWAY
STREET 2: SUITE 310
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 610-424-2650
MAIL ADDRESS:
STREET 1: 201 BROADWAY
STREET 2: SUITE 310
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Chardan Healthcare Acquisition 2 Corp.
DATE OF NAME CHANGE: 20200306
FORMER COMPANY:
FORMER CONFORMED NAME: Chardan Healthcare Acquisition III Corp.
DATE OF NAME CHANGE: 20200113
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: NYSE AMERICAN LLC
CENTRAL INDEX KEY: 0001143313
IRS NUMBER: 522127241
FILING VALUES:
FORM TYPE: 25-NSE
BUSINESS ADDRESS:
STREET 1: 11 Wall Street
CITY: New York
STATE: NY
ZIP: 10005
BUSINESS PHONE: 212-656-5414
MAIL ADDRESS:
STREET 1: 11 Wall Street
CITY: New York
STATE: NY
ZIP: 10005
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE MKT LLC
DATE OF NAME CHANGE: 20120514
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE Amex
DATE OF NAME CHANGE: 20090402
FORMER COMPANY:
FORMER CONFORMED NAME: NYSE Alternext US LLC
DATE OF NAME CHANGE: 20081009
25-NSE
1
primary_doc.xml
X0203
0001143313
NYSE AMERICAN LLC
0001799850
Renovacor, Inc.
001-39271
201 Broadway, Suite 310
Cambridge
MA
MASSACHUSETTS
02139
610-424-2650
Common Stock and Warrants
17 CFR 240.12d2-2(a)(3)
Daniel Contrastano
Manager, Market Watch & Proxy Compliance
2022-12-01
EX-99.25
2
ruleprovisionnotice.htm
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES
NYSE American LLC hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on December 12, 2022, pursuant to the provisions of Rule 12d2-2 (a).
[ X ] 17 CFR 240.12d2-2(a)(3) That on December 1, 2022 the instruments representing the securities comprising the entire class of this security came to evidence, by operation of law or otherwise, other securities in substitution therefore and represent no other right except, if such be the fact, the right to receive an immediate cash payment.
The merger between Renovacor, Inc. and Rocket Pharmaceuticals, Inc. became effective on December 1, 2022. Each share of Renovacor, Inc Common Stock was exchanged for 0.1676 of a share of Rocket Pharmaceuticals, Inc. and each Warrant, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11.50 per whole share of Renovacor, Inc will be assumed by Rocket Pharmaceuticals, Inc. and automatically converted into a warrant entitling the holder thereof to acquire a number of shares of Rocket common stock equal to the product of (i) the number of shares subject to such Renovacor public warrant multiplied by (ii) the exchange ratio, rounded down to the nearest whole number of shares of Rocket common stock, at an exercise price per share of Rocket common stock equal to the quotient obtained by dividing (A) the per share exercise price of such Renovacor public warrant by (B) the exchange ratio, rounded up to the nearest whole cent.
The Exchange also notifies the Securities and Exchange Commission that as a result of the above indicated conditions this security was suspended from trading on December 1, 2022.